Declining sustained virological response in hepatitis C

Uzma Batool; Saleem Qureshi

Author(s)

Uzma Batool Department of Medicine, KRL General Hospital, Islamabad. Pakistan.

Saleem Qureshi Department of Medicine, KRL General Hospital, Islamabad. Pakistan.

Abstract

Objective: To determine the response of treatment with standard interferon and Ribazole in treatment naive hepatitis C infected patients, with different grades of activity. Design: A quasi-experimental study. Place and Duration of Study: This study was carried out at the Department of Medicine, KRL General Hospital, Islamabad, from January 2001 to September 2004. Patients and Methods: A total of 300 patients were enrolled. All patients were anti-HCV positive confirmed by device method, PCR positive and had 3a genotype. A specially-designed proforma containing the patient profile, family transmission, and baseline laboratory values was filled. All patients were treated according to a set protocol of Interferon plus ribavirin therapy (IFN alpha 2a, 3MU t.i.w 24 weeks plus ribavirin 1000 to 1200 mg/day) for six months. Chi-square tests were used to analyze the data. Primary end point was a sustained virological response (SVR) that is response assessed after six months of completion of treatment. Results: Over a period of four years response rates to standard Interferon plus Ribazole therapy were studied. Out of the total 300 patients data was available for 161 patients as 60 patients were excluded and 79 patients are currently under treatment. Treatment was stopped in 3 patients due to serious side effects. In the 161 patients, 135 (83.8%), achieved response at the end of treatment at six months; End of Treatment Complete Response (EOTCR); and 26 (16.14%) were non-responders (NR). Out of the complete responders, 68 patients had been followed completely upto six months after the treatment to asses Sustained Viral Response (SVR) defined as undetectable HCV RNA in serum at the end of six months posttreatment follow-up. Sustained viral response was seen in 46 patients i.e. 68% ( Cl: 57-79%) and 22(32.3%) were relapsers (those who developed recurrence of viremia after having achieved eradication at the end of six months treatment). Response rates are co-related with gender, baseline ALT and necroinflammatory stage assessed by liver biopsy, probable risk factors and positive family history. Conclusion: Management of hepatitis C with genotype 3a, with standard Interferon and Ribazole for six months appear to show declining SVR compared to that reported in previous international and local data.

Publication Details

Page(s) 187-191

DOI DOI not available

Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 16, Issue: 3, Year: 2006

Request the full text from PASTIC

Keywords

Interferon, Sustained viral response, HCV, Response rates

References

.2005 .. Peginterferaolfan-2bandribavirfionr12 vs.24 weeksinHCV genotyp2eor3. N Engl]Med, 352 : 2609-17.

.2002 .interferopnlus ribaviri nin themanagemenotf chronic hepatitCis. J CollPhysicians Surg Pak, 12 : 609-12.

. .. , 5 : 19-26.

Hamid S,Ahmed Z,Siddiqui S.,Jan MA .2004 .IntJ Infect 16. JPostgradMedInst, 18 : 563-8.

Kazmi Y .2002 .. Treatmenrtesponsien HCV relatedchronic hepatitiCso.l/l Physicians Surg Pak, 12 : 609-12.

.1997 .. Hepatology, 26(3) : 2S-10S.

.2001 .-b plusribavircinompared withinterferaolnfa-2bplusribavirfionrinitiatlreatmeonftchronic hepatitCis; a randomizetdriaLl. ancet, 358 : 958-65.

.1997 .. , 26(3) : 128S-32S.

Lee SS,BalarLt SS .2000 .. Peginterferaolfan-2ain patientwsithhepatitCis andcirrhosNisE.ngl]Med, 343 : 1673-80.

Fried MW,Reddy KR,Smith C .2002 .47 (RR- hepatitCisvirusinfectioNn. EnglJMed, 347 : 1-39.

Lee SS .1998 .Randomizedtriaolf interferaolnpha-2bplusribavirifnor48 weeksversuisnterferanlpha-2bplusplacebofor48 weeksfor treatmeonftchronincfectiownithhepatitCisvirus. Lancet, 352 : 1426-32.

Levy S .1997 .Therapyof hepatitCis patients withnormaolrabnormaal laninetransaminalseevels. Hepatology, 26(3) : 133S-6S.

.1997 .Clinical,histologicaanl,d virologicfeaaltureosf hepatitCisvirus carrierwsith persistentnlyormal or abnormalalanine transaminalseveels. Hepatology, 26 : 1393-8.

C .2002 .. , 37 : 837-42.

.2002 .HepatitiCs and steatosSisem. in Gastrointest Dis, 13 : 40-6.

.2002 .Peginterfer-aolnfa2a in combinatiownithribavirinef:ficacyand safetyresultfrsomphase III, randomizedd,oubleblind multi-centsetrudyexaminingeffect ofduratioonftreatmeanntd RB\l. JHepatol, 36(suppl1) : 1.

Me HutchisoJGn .2001 .-2b plus ribavirinforinitialtreatmenotf Expressioonf liversteatosiins hepatitiCs virusinfectioannd chronhicepatitCis: a randomizetdriaLl. atol, 35 : 307-65.